Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–9 of 9 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +21 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
NCT02713386
- Conditions
- Adnexal Diseases, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, +35 more
- Locations
-
- CTCA at Western Regional Medical Center Goodyear, Arizona, United States
- Sutter Auburn Faith Hospital Auburn, California, United States
- UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
- Sutter Roseville Medical Center Roseville, California, United States
Active, Not Recruiting
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
- Locations
-
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
Active, Not Recruiting
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT04092270
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
- Locations
-
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
Active, Not Recruiting
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT04616534
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Active, Not Recruiting
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03587311
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, +5 more
- Locations
-
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
Active, Not Recruiting
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04034927
- Conditions
- Adnexal Diseases, Fallopian Tube Diseases, Fallopian Tube Endometrioid Tumor, +23 more
- Locations
-
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- Hartford Hospital Hartford, Connecticut, United States
- Augusta University Medical Center Augusta, Georgia, United States
Active, Not Recruiting
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02659241
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, +34 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States
- MD Anderson in The Woodlands Conroe, Texas, United States
- Memorial Hermann Memorial City Medical Center Houston, Texas, United States
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT05276973
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +32 more
- Locations
-
- UCSF Medical Center-Mission Bay San Francisco, California, United States
- Augusta University Medical Center Augusta, Georgia, United States
- Cleveland Clinic Foundation Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States